Skip to main content
Screenshot of anzupgo.com

Live website intelligence

anzupgo.com

Anzupgo® (delgocitinib) Cream 2% for Chronic Hand Eczema

Anzupgo® (delgocitinib) Cream 2% is the first and only FDA-approved treatment made for chronic hand eczema—relief from itch, pain, and flares starts here.

Last refresh

Updated 15d ago

Analyst read

Professional

#611.3K global rank5/100 trustHealth & FitnessStale snapshot

Detected stack

React

Quick read

How to read anzupgo.com quickly

anzupgo.com looks like health & fitness. Traffic signals point to roughly 70.4K monthly visits. Current AI trust scoring is 5/100.

What to do next

  • The stack appears to include React.
  • Open the Traffic tab if you need audience scale and geography before outreach.
  • Open the Business tab if trust, monetization, or positioning is your first decision filter.

Provider Completeness

51/56 fields populated (91%)

11 providers

Providers with missing fields

publisher: 3/5files: 2/3radar: 2/4
View field-level status

visual: 4/4

All expected fields present

meta: 3/3

All expected fields present

seo: 5/5

All expected fields present

dns: 4/4

All expected fields present

ads: 5/5

All expected fields present

publisher: 3/5

Missing: directCount, resellerCount

files: 2/3

Missing: robotsSitemapUrls

traffic: 10/10

All expected fields present

whois: 6/6

All expected fields present

radar: 2/4

Missing: categories, sourceTimestamp

ai: 7/7

All expected fields present

Why this module matters

Business signals help answer “is this a real opportunity?”

Use the business tab to understand trust, monetization, audience fit, and brand posture before you spend time on outreach, partnerships, or competitive teardown work.

  • Trust score and sentiment are your first risk screen.
  • Business summary and audience notes speed up qualification.
  • Ads and monetization patterns reveal how the site captures value.

Business Intelligence

Business Profile

Anzupgo (delgocitinib) Cream 2% is a prescription pharmaceutical product marketed as the first and only FDA-approved treatment specifically for adults with moderate-to-severe chronic hand eczema (CHE). The website serves as a patient and healthcare professional resource for product information, safety details, and savings programs.

Business ModelPharmaceutical/Medical Product
Target AudienceAdults suffering from moderate-to-severe chronic hand eczema, their caregivers, and healthcare professionals (dermatologists, primary care physicians)

Classification

CategoryHealth & Fitness
Sub-CategoryMedicine
pharmaceuticaldermatologyeczemaprescriptionFDA-approvedtopical treatmentchronic hand eczemadelgocitinib

Trust & Risk

Trust Assessment

Trust Score5/100
SentimentProfessional
Spam DetectionClean

Google Ads Transparency

Is AdvertiserActive Advertiser
Advertiser Names
LEO Pharma Inc.
Advertiser IDs
AR13877751000867012609
Ad Count1
has_advertiser_idhas_creative_results

Publisher Monetization

ads.txtMissing

Monetization Signals

missing_ads_txt

AI Visual Analysis

Design StyleCorporate Healthcare
VibeTrustworthy, Clean, Reassuring, Professional
UI Score8/100
Detected Logo TextAnzupgo (delgocitinib) cream 2%

IAB Taxonomy

IAB CategoryHealth & Fitness
IAB Sub-CategoryMedicine
Confidence98%
pharmaceuticaldermatologyeczemaprescriptionFDA-approvedtopical treatmentchronic hand eczemadelgocitinib

Business Insights

Business Model

Pharmaceutical/Medical Product model detected

Trust Level

Low trust with 5/100 score

Audience

Adults suffering from moderate-to-severe chronic hand eczema, their caregivers, and healthcare professionals (dermatologists, primary care physicians)

Keep exploring

Keep exploring from this report

Good pSEO pages should not strand the visitor. These links keep the journey moving through adjacent directories and comparable live reports.

Need fresh data for another site? Trigger a fresh analysis or open the directory to continue browsing.